 |
Prospector
Profile
1203-02
|
| |
| Dynavax Technologies |
NAICS |
541710 |
| 2929 Seventh Street, Suite 100
Berkeley, CA 94710 |
Description |
Biotechnology |
| (510) 848-5100 |
Employees |
153 |
| http://www.dynavax.com/ |
Revenue |
(mil) |
4.8470 |
| |
Income |
(mil) |
-52.0520 |
| |
Assets |
(mil) |
102.8900 |
| |
Liability |
(mil) |
77.0560 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Dynavax Technologies Corp. had a net loss of $17.1 million on sales of $1.01 million for the three months ended September 30, 2007, much higher than the $12.15 million net loss on sales of $1.6 million reported during the three months ended September 30, 2006. For the six months ended September 30, 2007, the Company had a $47.9 million net loss, much higher than the $35.6 million net loss reported during the nine months ended September 30, 2006. As a result of its recurring losses, the Company has an accumulated deficit of $215.84 million in its September 30, 2007 balance sheet.
|
| |
|
Intellectual Property:
The Company has 48 issued U.S. and foreign patents, 31 pending U.S. patent applications, and 91 pending foreign applications that seek worldwide coverage of compositions and methods using ISS technology. Some of these patents and applications have been exclusively licensed worldwide from the Regents of the University of California. It also has 27 issued U.S. and foreign patents and 5 pending U.S. and foreign patent applications covering methods and compositions for vaccines using DNA and methods for their use. It holds an exclusive, worldwide license from the Regents of the University of California for patents and patent applications relating to vaccines using DNA, and has the right to grant sublicenses to third parties. In addition, the Company has 2 issued U.S. and foreign patents and 7 pending U.S. and foreign patent applications providing worldwide rights to certain compositions and methods using IRS (including immunoinhibitory sequences). [SEC Filing 10-K 03-16-07]
|
| |
|
Description:
The Company engages in the discovery and development of Toll-like Receptor 9 (TLR9), agonist-based products to treat and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases.
|
| |
|
Officers:
Arnold Oronsky (Chair); Dino Dina (Pres., CEO & Dir.); Deborah A. Smeltzer (VP & CFO); Timothy G. Henn (VP & Chief Acctg. Officer); Nancy L. Buc (Dir.); Dennis Carson (Dir.); Denise M. Gilbert (Dir.); David M. Lawrence (Dir.); Peggy V. Phillips (Dir.); Stanley A. Plotkin (Dir.)
|
| |
|
Auditor:
Ernst & Young LLP
|
| |
|
Securities:
Common Stock-Symbol DVAX; NasdaqGM;
39,764,520 common shares outstanding as of October 31, 2007.
|
| |
| |
| |
| return to main page |
|
|
